Select publications

Annuska M et al. Gene expression profiles are best suited to assess present though not future clinical aggressiveness in follicular lymphoma. Proc ASH 2004;Abstract 698.

Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract

Liu Q et al. Stage IV indolent lymphoma: 25 years of treatment progress. Proc ASH 2003;Abstract 1446.

McLaughlin P et al. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 1993;4(3):205-11. Abstract

McLaughlin P et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33. Abstract

McLaughlin P et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000;27(6 Suppl 12):37-41. Abstract